Streetbeat News

Products Services

PMBHF

PharmAla Biotech Holdings (OTC:PMBHF) has filed a patent for a Novel Chemical Entity (NCE) PharmAla-1, discovered through computational in-silico modeling. The molecule has undergone a year of preclinical research and shows potential for treating Autism Spectrum Disorder (ASD). The company believes PharmAla-1 will have an improved toxicology profile compared to traditional MDXX compounds. PharmAla's drug development pipeline is set to advance throughout 2023, with the ALA family soon moving into clinical development.

Portfolio Pulse from Lara Goldstein

July 31, 2023 | 10:06 pm

GOOG

GOOGL

Alphabet Inc is planning a significant overhaul of its Google Assistant, incorporating generative AI technologies. The change will affect end-users, developers, and Google's staff. The overhaul has already started with the mobile version of the product. As part of this shift, Google is reorganizing the teams responsible for Assistant, leading to some job cuts. Google has also initiated Project Tailwind, a program designed to offer users access to private and personalized AI.

Portfolio Pulse from Piero Cingari

July 31, 2023 | 10:05 pm

UBSFF

Ubisoft Entertainment SA's upcoming game 'Assassin’s Creed Mirage' will take players an average of 20 to 24 hours to complete, signaling a return to the franchise's older, classic style. The game features a smaller map, focusing on a single city. Ubisoft has also partnered with Spanish company OWO to create a haptic feedback vest for the game. The game is set to be released on October 12.

Portfolio Pulse from Franca Quarneti

July 31, 2023 | 10:02 pm

EBS

Emergent Biosolutions has been awarded a 10-year contract by BARDA for the development of an Ebola treatment, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 9:50 pm

AFMD

Affimed has reported a breakthrough poster presentation at ASCO with clinical data of AFM24 in combination with NKGen Biotech's SNK01 NK Cells. Stable disease was observed in three out of seven heavily pretreated patients. No dose-limiting toxicities or unexpected toxicities were observed.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 9:41 pm

TKLF

Yoshitsu Co., Ltd (NASDAQ:TKLF) reported its FY23 financial results, showing a decrease in EPS from $0.12 YoY to $(0.22) and a drop in revenue from $234.75M YoY to $169.72M. The company attributed these results to the global pandemic and currency fluctuations. However, Yoshitsu highlighted strategic successes, including a shift in geographic market strategy towards the domestic Japan market and a focus on franchise stores and wholesale customers. The company also plans to expand overseas and develop a new shopping App to attract worldwide shoppers.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 9:40 pm

GOOG

GOOGL

Google plans to revamp its Assistant using generative AI technologies similar to those that power ChatGPT and its own Bard chatbot. The move will change how Assistant works for consumers, developers, and Google's own employees. The company is reorganizing the teams that work on Assistant and making a small number of layoffs. Other companies, including Amazon, are making similar moves.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 9:29 pm

CDTX

Cidara Therapeutics has announced that its commercial partner has initiated the commercial launch of REZZAYO, a new drug in their portfolio.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 9:20 pm

INTS

PRTG

Portage Biotech Inc. (NASDAQ:PRTG) reported a net loss of $104.7 million for the fiscal year ended March 31, 2023, compared to a net loss of $19.2 million for the previous year. The company also announced progress in its clinical programs, including the dosing of the first patient in its adaptive Phase 1a/1b trial, ADPORT-601, evaluating PORT-6, an adenosine 2A receptor antagonist candidate. Portage has also entered into a clinical collaboration agreement with Merck for the evaluation of PORT-2, in combination with KEYTRUDA, Merck's anti-PD-1 therapy.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 9:15 pm

DBVT

DBV Technologies has received feedback from the U.S. Food and Drug Administration (FDA) on its two supplemental safety studies for Viaskin Peanut in toddlers and children. The company plans to seek final alignment with the FDA on the COMFORT protocols before starting the studies. DBV closed Q2 2023 with a cash balance of $174 million.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 8:47 pm